Fig. 5: Inhibiting autophagy amplified the in vivo antitumor effectiveness of αCLDN18.2-MMAE. | Cell Death Discovery

Fig. 5: Inhibiting autophagy amplified the in vivo antitumor effectiveness of αCLDN18.2-MMAE.

From: Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer

Fig. 5

A, C MKN45-CLDN18.2 cells were subcutaneously implanted in NCG mice to establish xenograft models. αCLDN18.2-MMAE (2 mg/kg), with or without LY294002 (50 mg/kg), was administered twice a week for three weeks. Tumor volume was monitored every three days. Results were presented as mean and error ± S.D. (n = 6). B At the experimental endpoint, all mice were sacrificed and tumor weight was measured (n = 6). Data were analyzed by two-tailed unpaired t-test (**P < 0.01) D H&E and immunohistochemical staining of cleaved caspase-3 and Ki-67 in tumor tissues. Scale bar = 20 μm.

Back to article page